flurbiprofen has been researched along with Aging in 16 studies
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.
flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flurbiprofen is a chiral nonsteroidal anti-inflammatory drug (NSAID) of the 2-arylpropionic acid class." | 2.39 | Clinical pharmacokinetics of flurbiprofen and its enantiomers. ( Davies, NM, 1995) |
| "R-flurbiprofen was used because it is able to reduce neuropathic pain in young mice in part by increasing anandamide." | 1.39 | Anandamide deficiency and heightened neuropathic pain in aged mice. ( Bishay, P; Ferreirós, N; Galve-Roperh, I; Häussler, A; Lim, HY; Oertel, B; Tegeder, I, 2013) |
| " This pharmacokinetic study was an effort to understand the pharmacodynamic difference between the two routes of administration observed when the same dose range of drug, given as single daily doses, had been employed in both studies." | 1.29 | Chiral pharmacokinetics of Rac-flurbiprofen and pharmacodynamics of anabolic bone response in the normal rat. ( Bigornia, AE; Jee, WS; Murray, ED; Wechter, WJ, 1994) |
| "The pharmacokinetic profile of 200 mg sustained-release flurbiprofen capsules was compared in nine elderly (mean age 84." | 1.28 | A multiple dose pharmacokinetic and tolerance study of once daily 200 mg sustained-release flurbiprofen capsules in young and very elderly patients. ( Bird, A; Hamdy, RC; Hill, J; Hind, ID; Le Gallez, P, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 5 (31.25) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bishay, P | 1 |
| Häussler, A | 1 |
| Lim, HY | 1 |
| Oertel, B | 1 |
| Galve-Roperh, I | 1 |
| Ferreirós, N | 1 |
| Tegeder, I | 1 |
| Calvo-Rodríguez, M | 1 |
| García-Durillo, M | 1 |
| Villalobos, C | 1 |
| Núñez, L | 1 |
| Montine, TJ | 1 |
| Larson, EB | 1 |
| Holtzman, JL | 1 |
| L'episcopo, F | 1 |
| Tirolo, C | 1 |
| Testa, N | 1 |
| Caniglia, S | 1 |
| Morale, MC | 1 |
| Impagnatiello, F | 1 |
| Marchetti, B | 1 |
| Patel, BK | 1 |
| Jackson, SH | 1 |
| Swift, CG | 1 |
| Hutt, AJ | 1 |
| Beckman, M | 1 |
| Miller, RA | 1 |
| Harrison, DE | 1 |
| Astle, CM | 1 |
| Floyd, RA | 1 |
| Flurkey, K | 1 |
| Hensley, KL | 1 |
| Javors, MA | 1 |
| Leeuwenburgh, C | 1 |
| Nelson, JF | 1 |
| Ongini, E | 1 |
| Nadon, NL | 1 |
| Warner, HR | 1 |
| Strong, R | 1 |
| Imbimbo, BP | 1 |
| Del Giudice, E | 1 |
| Colavito, D | 1 |
| D'Arrigo, A | 1 |
| Dalle Carbonare, M | 1 |
| Villetti, G | 1 |
| Facchinetti, F | 1 |
| Volta, R | 1 |
| Pietrini, V | 1 |
| Baroc, MF | 1 |
| Serneels, L | 1 |
| De Strooper, B | 1 |
| Leon, A | 1 |
| Davies, NM | 1 |
| Wechter, WJ | 1 |
| Bigornia, AE | 1 |
| Murray, ED | 1 |
| Jee, WS | 1 |
| Hobden, JA | 1 |
| Hill, JM | 1 |
| Engel, LS | 1 |
| O'Callaghan, RJ | 1 |
| Fowler, CJ | 1 |
| Janson, U | 1 |
| Johnson, RM | 1 |
| Wahlström, G | 1 |
| Stenström, A | 1 |
| Norström, K | 1 |
| Tiger, G | 1 |
| Innes, EH | 1 |
| McKenzie, LS | 1 |
| Horsburgh, BA | 1 |
| Ghosh, P | 1 |
| Taylor, TK | 1 |
| Hamdy, RC | 1 |
| Bird, A | 1 |
| Le Gallez, P | 1 |
| Hill, J | 1 |
| Hind, ID | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease[NCT03277573] | Phase 1 | 40 participants (Anticipated) | Interventional | 2017-07-21 | Active, not recruiting | ||
| Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects[NCT00954252] | Phase 1 | 84 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for flurbiprofen and Aging
| Article | Year |
|---|---|
Clinical pharmacokinetics of flurbiprofen and its enantiomers.
Topics: Absorption; Administration, Oral; Aging; Blood Proteins; Delayed-Action Preparations; Dose-Response | 1995 |
1 trial available for flurbiprofen and Aging
| Article | Year |
|---|---|
Efficacy and tolerance of flurbiprofen in the elderly using liquid and tablet formulations.
Topics: Aged; Aging; Dosage Forms; Female; Flurbiprofen; Hip Joint; Humans; Male; Osteoarthritis; Palliative | 1977 |
14 other studies available for flurbiprofen and Aging
| Article | Year |
|---|---|
Anandamide deficiency and heightened neuropathic pain in aged mice.
Topics: Aging; Amidohydrolases; Animals; Arachidonic Acids; Behavior, Animal; Brain; Cyclooxygenase 1; Cyclo | 2013 |
Aging Enables Ca2+ Overload and Apoptosis Induced by Amyloid-β Oligomers in Rat Hippocampal Neurons: Neuroprotection by Non-Steroidal Anti-Inflammatory Drugs and R-Flurbiprofen in Aging Neurons.
Topics: Aging; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Calcium; | 2016 |
Late-life dementias: does this unyielding global challenge require a broader view?
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Comorbidity; | 2009 |
Are we prepared to deal with the Alzheimer's disease pandemic?
Topics: Aging; Alzheimer Disease; Alzheimer Vaccines; Amyloid beta-Peptides; Animals; Disease Outbreaks; Flu | 2010 |
Switching the microglial harmful phenotype promotes lifelong restoration of subtantia nigra dopaminergic neurons from inflammatory neurodegeneration in aged mice.
Topics: Aging; Animals; Dopaminergic Neurons; Flurbiprofen; Inflammation; Lipopolysaccharides; Male; Mice; M | 2011 |
Disposition of flurbiprofen in man: influence of stereochemistry and age.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Anti-Inflammatory Agents, | 2003 |
Placing bets. National Institute on Aging committee chooses three compounds for definitive longevity testing.
Topics: Aging; Animals; Aspirin; Flurbiprofen; Longevity; Mice; National Institutes of Health (U.S.); United | 2004 |
An Aging Interventions Testing Program: study design and interim report.
Topics: Aging; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Cyclic N-Oxides; Dru | 2007 |
1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor P | 2007 |
Chiral pharmacokinetics of Rac-flurbiprofen and pharmacodynamics of anabolic bone response in the normal rat.
Topics: Administration, Oral; Aging; Animals; Bone Development; Female; Flurbiprofen; Injections, Subcutaneo | 1994 |
Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen.
Topics: Aging; Animals; Aqueous Humor; Biological Assay; Ciprofloxacin; Cornea; Drug Therapy, Combination; F | 1993 |
Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and flurbiprofen.
Topics: Aging; Animals; Arachidonic Acids; Brain; Cell Extracts; Cell Survival; Dose-Response Relationship, | 1999 |
Effect of anti-inflammatory drugs on sulphated glycosaminoglycan synthesis in aged human articular cartilage.
Topics: Aged; Aging; Anti-Inflammatory Agents; Cartilage, Articular; Depression, Chemical; Flurbiprofen; Gly | 1976 |
A multiple dose pharmacokinetic and tolerance study of once daily 200 mg sustained-release flurbiprofen capsules in young and very elderly patients.
Topics: Adult; Aged; Aged, 80 and over; Aging; Arthritis, Rheumatoid; Capsules; Delayed-Action Preparations; | 1990 |